Remarkably, elevated expression levels of UBE2V1/2 correlate with improved survival rates in human colorectal cancer patients harboring oncogenic <i>KRAS</i> mutations, indicating that their upregulation could represent a promising therapeutic strategy. This evidence concerns the gene KRAS and colorectal cancer.